USA flag logo/image

An Official Website of the United States Government

Objective Method for Pain Detection/Diagnosis

Award Information

Agency:
Department of Defense
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
H122-015-0012
Solicitation Year:
2012
Solicitation Topic Code:
DHP12-015
Solicitation Number:
2012.2
Small Business Information
BioSensics LLC
678 Mass. Ave., Suite 904 Cambridge, MA 02139-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2013
Title: Objective Method for Pain Detection/Diagnosis
Agency: DOD
Contract: W81XWH-13-C-0095
Award Amount: $149,988.00
 

Abstract:

Pain is subjective and inherently difficult to quantify, yet appropriate pain management is predicated on adequate assessment. Whenever possible, pain is measured by the patient"s self-report. Patients who cannot reliably self-report are at significantly higher risk for inadequately managed pain. Therefore, there is a need for objective pain monitoring for noncommunicative patients. BioSensics LLC, in partnership with the University of Arizona, will develop a Multimodal Objective Pain Assessment Sensor System (MoPASS) consisting of two light, comfortable, wireless, wearable sensors (on the fingers and forehead) to monitor multiple indicators of pain and provide a single pain intensity score. This pain score will be based on proven pain correlates including behavioral parameters (restlessness and facial expression) and physiological parameters (electrocortical activity, heart-rate, skin conductance, and skin temperature). This system has broad applications ranging from rapid assessment in field-clinics to long-term monitoring of chronically noncommunicative patients. In Phase I we will develop the sensor system and perform a clinical feasibility study. In Phase II we will perform a comprehensive clinical study to examine the sensitivity and specificity of MoPASS. The results of this study will be used to pare down our system to the fewest possible sensing modalities for commercialization in Phase III.

Principal Investigator:

Bor-rong Chen
Chief Technology Officer
(888) 589-6213
bor-rong.chen@biosensics.com

Business Contact:

Joseph Gwin
Vice President of Research and Dev
(888) 589-6213
joseph.gwin@biosensics.com
Small Business Information at Submission:

BioSensics LLC
165 Pleasant St., Suit 302 Cambridge, MA -

EIN/Tax ID: 260547866
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No